Finally! Be free from smoking

Archive for the ‘Treatment’ Category

Debi wrote an interesting post today on
Here’s a quick excerpt
Scientists have identified a new molecular marker in blood which could indicate how patients with a type of lung cancer will respond to treatment, according to research published in Clinical Cancer Research.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
 Lung cancer creates enough heartache to begin with, but it breaks my heart when complications – especially those that can be prevented or treated if detected early – lead to further illness and possibly death. As we place our focus on curing cancer, it is possible to overlook one problem that can be equally deadly. Blood clots.

Read the rest of this great post here

nospam@example.com (Clear the Smoke) wrote an interesting post today on
Here’s a quick excerpt
French biotech company Transgene said on Monday that further clinical results showed the survival benefits of its therapeutic vaccine TG4010 in treating patients with advanced non-small cell lung cancer.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
An innovative trial has shown pazopanib, a new oral angiogenesis inhibitor, to demonstrate interesting activity in difficult to treat non-small-cell lung cancer. 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumour size shrink by up to 85% in the phase II trial announced at the 33rd European Society for Medical Oncology meerting in Stockholm.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
 Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
The targeted therapy gefitinib should be considered first-line in nonsmoking, chemotherapy-naïve Asian patients with advanced non-small-cell lung cancer (NSCLC), according to the results of the phase 3 study presented here at the 33rd European Society for Medical Oncology Congress (ESMO).
The First Line IRESSA Versus Carboplatin/Paclitaxel in Asia (IPASS) study — heralded as proof of principle for targeted chemotherapy in lung cancer — demonstrated progression-free survival advantages for gefitinib over the standard-of-care therapy (combination carboplatin/paclitaxel

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
Swiss drugmaker Roche said on Monday phase III trial data showed that Avastin combined with gemcitabine-cisplatin chemotherapy improved the time patients lived without lung cancer progressing.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
A new procedure called Radio Frequency Ablation (RFA) uses radio waves to fight the onslaught of cancer in the lungs. While RFA is mostly a palliative treatment, the good news is that the procedure is non-invasive; heat directly applied to the tumor through a needle-fine probe does the job.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
Celgene Corp. a pharmaceutical company based in Summit, today announced that its lung cancer drug, “Amrubicin,” has been granted “fast track” approval by the U.S. Food and Drug Administration. Amrubicin is for the treatment of small cell lung cancer after chemotherapy, the company said in a statement.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
University of Cincinnati ( UC ) oncologists are involved in one of the largest international cancer vaccine clinical trials to date aimed at reducing recurrence and improving life expectancy among early-stage lung cancer survivors. 
Led locally by Apurva Mehta, MD, the phase-3 trial is expected to enroll a total of 2,300 patients through 100 centers in the United States and 400 globally. Mehta is looking for about five local patients who have stage IB through stage IIIA non small-cell lung cancer to participate in the study.

Read the rest of this great post here